Arqule Inc (NASDAQ:ARQL) Sellers Declined By 7.4% Their Shorts

May 16, 2018 - By Mary Markley

ArQule, Inc. (NASDAQ:ARQL) Corporate Logo

Arqule Inc (NASDAQ:ARQL) showed a decrease of 7.4% in shorted shares. In May was announced ARQL’s total 1.56 million shorted shares by FINRA. The 1.68 million previous shares are down with 7.4%. With Average volume 1.31M, ARQL’s former position will take 1 days to restore. Float short on Arqule Inc is 2.81%.

The stock increased 4.92% or $0.16 during the last trading session, touching $3.41.ArQule, Inc. has 1.34 million shares volume, 37.90% up from normal. ARQL is uptrending and has moved 180.00% since May 16, 2017. ARQL outperformed the S&P500 by 168.45%.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States.The company has $297.10 million market cap. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.Currently it has negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

ArQule, Inc. (NASDAQ:ARQL) Ratings Coverage

Total analysts of 5 have positions in Arqule (NASDAQ:ARQL) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 14, 2017 according to StockzIntelligence Inc Arqule has 5 analyst reports. On Thursday, December 14 the rating was upgraded by Needham to “Buy”. In Thursday, April 5 report Leerink Swann upgraded it to “Buy” rating and $500 target. In Friday, February 2 report FBR Capital initiated the stock with “Buy” rating. On Monday, February 12 the firm has “Buy” rating given by B. Riley & Co.

ArQule, Inc. (NASDAQ:ARQL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.